NCT00002010已完成不适用
Open, Non-Comparative Study of Fluconazole in Patients With Coccidioidal Meningitis
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 试验地点
- 3
研究概览
简要总结
The study is intended to examine the efficacy of fluconazole for the treatment of coccidioidal meningitis in patients with new onset of infection, relapse of previous infection, or failed previous therapy. Drug efficacy, safety and tolerance will be examined.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Immunosuppressive therapy including corticosteroids and/or cytotoxic agents.
- •Antiviral therapy (e.g., zidovudine (AZT)).
- •Prophylaxis for Pneumocystis carinii pneumonia (PCP).
- •Any exceptions to use of concomitant medications must be approved by Pfizer Central Research prior to study entry.
- •Concurrent Treatment:
- •Radiation therapy for mucocutaneous Kaposi's sarcoma.
- •Patients must:
- •Be clinically judged to be in need of treatment for coccidioidal meningitis.
- •Have > 1 week life expectancy.
- •Immunocompromised patients.
- •Patients with renal disease will have the dose of fluconazole adjusted and serum levels may be monitored.
- •Prior Medication:
- •Amphotericin B.
- •Ketoconazole.
- •Miconazole.
排除标准
- •Co-existing Condition:
- •Patients with the following conditions or symptoms are excluded:
- •Current antifungal infection that is responding to another agent. Findings of improvement include one of the following, while on other therapy (without subsequent relapse of the item):
- •CSF culture conversion from positive to negative.
- •CSF antibody titer decrease of at least one dilution.
- •Improvement in signs and symptoms of meningitis.
- •Have received more than minimal systemic antifungal therapy (see Patient Inclusion Criteria), unless they meet criteria for previous treatment failure or relapse. They must not have received this therapy since the time relapse or failure was documented, except for minimal antifungal therapy allowed in Patient Inclusion Criteria.
- •Immediately life-threatening coccidioidomycosis defined as infection of such a degree of clinical severity that the patient would be expected to die within 1 week, if untreated, based on clinical judgment.
- •Experienced a prior allergic reaction or major side effect from an imidazole or triazole compound.
- •Concurrent Medication:
- •Barbiturates.
- •Phenytoin.
- •Oral hypoglycemics.
- •Coumadin type anticoagulants.
- •Other systemic or intrathecal antifungal therapy.
- •Other experimental agents with exceptions noted in concomitant medications section.
- •Any exceptions to these prohibitions of concomitant medications must be approved by Pfizer Central Research prior to study entry.
- •Patients with the following are excluded:
- •Are responding or are improving on current antifungal therapy with another agent.
- •Have received more than minimal systemic antifungal therapy (see Patient Inclusion Criteria), unless they meet criteria for previous treatment failure or relapse. They must not have received this therapy since the time relapse or failure was documented, except for minimal antifungal therapy allowed in Patient Inclusion Criteria.
- •Immediately life-threatening coccidioidomycosis defined as infection of such a degree of clinical severity that the patient would be expected to die within 1 week, if untreated, based on clinical judgment.
- •Experienced a prior allergic reaction or major side effect from an imidazole or triazole compound.
研究者
研究点 (3)
Loading locations...
相似试验
已完成
不适用
A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are CommonMycosesCoccidioidomycosisHIV InfectionsNCT00002325Pfizer
已完成
3 期
A Study Of Diflucan In Children With Ringworm Of The ScalpTinea CapitisNCT00645242Pfizer185
已完成
不适用
Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal TherapyMycosesCandidiasisHIV InfectionsNCT00002038Pfizer
已完成
1 期
Effect of Fluconazole on the Pharmacokinetics of Pyrotinib in Healthy SubjectsHealthy SubjectsNCT04850651Jiangsu HengRui Medicine Co., Ltd.18
已完成
3 期
Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection.Invasive CandidiasesNCT05848492Services Institute of Medical Sciences, Pakistan110